We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+26.7%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.55B
AUM Growth
+$135M
Cap. Flow
-$139M
Cap. Flow %
-8.96%
Top 10 Hldgs %
73.16%
Holding
30
New
1
Increased
5
Reduced
9
Closed
3

Top Buys

Rank Stock Value
1
BBOT
BridgeBio Oncology
BBOT
+$20.4M
2
ELVN icon
Enliven Therapeutics
ELVN
+$6.89M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$2.4M
4
APGE icon
Apogee Therapeutics
APGE
+$1.93M
5
AVBP icon
ArriVent BioPharma
AVBP
+$1.38M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$58.8M
2
BPMC
Blueprint Medicines
BPMC
+$34M
3
CBLL
CeriBell Inc
CBLL
+$16.9M
4
ASML icon
ASML
ASML
+$15.7M
5
BABA icon
Alibaba
BABA
+$15.1M

Sector Composition

Rank Sector Weight
1 Healthcare 50.22%
2 Technology 14.29%
3 Financials 10.3%
4 Consumer Discretionary 2.96%
5 Industrials 0.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTI icon
1
Vanguard Morningstar Total Stock Market ETF
VTI
$646B
$341M 21.97%
1,038,550
– –
BN icon
2
Brookfield
BN
$102B
$160M 10.3%
3,496,245
– –
ASML icon
3
ASML
ASML
$596B
$141M 9.1%
145,836
-20,000
-12% -$15.7M
MIRM icon
4
Mirum Pharmaceuticals
MIRM
$6.56B
$92.7M 5.97%
1,264,028
-236,027
-16% -$15M
EWTX icon
5
Edgewise Therapeutics
EWTX
$4.28B
$86.8M 5.59%
5,350,000
– –
CRM icon
6
Salesforce
CRM
$154B
$78.3M 5.04%
330,187
– –
MRUS
7
DELISTED
Merus
MRUS
$70.6M 4.55%
750,000
– –
CRNX icon
8
Crinetics Pharmaceuticals
CRNX
$8.88B
$67.7M 4.36%
1,625,000
+75,000
+5% +$2.4M
VRDN icon
9
Viridian Therapeutics
VRDN
$2.2B
$51.4M 3.31%
2,380,000
– –
BABA icon
10
Alibaba
BABA
$276B
$46M 2.96%
257,327
-115,000
-31% -$15.1M
ZBIO
11
Zenas BioPharma
ZBIO
$1.96B
$44.4M 2.86%
2,000,000
-250,000
-11% -$4.07M
PHVS icon
12
Pharvaris
PHVS
$2.28B
$43.7M 2.81%
1,750,000
+25,000
+1% +$555K
RXRX icon
13
Recursion Pharmaceuticals
RXRX
$1.58B
$38.7M 2.49%
7,929,835
-1,735,293
-18% -$9.11M
AVBP icon
14
ArriVent BioPharma
AVBP
$1.4B
$35.8M 2.31%
1,942,142
+70,000
+4% +$1.38M
BMRN icon
15
BioMarin Pharmaceuticals
BMRN
$11.9B
$35.7M 2.3%
660,000
– –
PCVX icon
16
Vaxcyte
PCVX
$7.65B
$33M 2.13%
916,160
– –
CLDX icon
17
Celldex Therapeutics
CLDX
$2.94B
$31M 2%
1,200,000
– –
ELVN icon
18
Enliven Therapeutics
ELVN
$3.78B
$29.2M 1.88%
1,426,260
+341,828
+32% +$6.89M
INSM icon
19
Insmed
INSM
$22.4B
$28.8M 1.86%
200,000
-480,000
-71% -$58.8M
VALN
20
Valneva
VALN
$518M
$28.6M 1.84%
2,345,000
-30,000
-1% -$256K
BBOT
21
BridgeBio Oncology
BBOT
$660M
$22.7M 1.46%
+1,961,317
New +$20.4M
APGE icon
22
Apogee Therapeutics
APGE
$10.1B
$19.9M 1.28%
500,000
+50,608
+11% +$1.93M
FDMT icon
23
4D Molecular Therapeutics
FDMT
$502M
$17.4M 1.12%
2,000,000
– –
LNZA icon
24
LanzaTech
LNZA
$59.9M
$3.88M 0.25%
158,148
– –
MQ icon
25
Marqeta
MQ
$1.93B
$2.33M 0.15%
110,390
– –
1
2

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return

Novo Holdings A/S's Q3 2025 Portfolio in Review

As of Q3 2025, Novo Holdings A/S held 30 positions worth $1.55B, up 9.5% from $1.42B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Novo Holdings A/S withdrew a net $139M in Q3 2025, closing 3 positions and reducing 9 holdings. Its most notable exit was Blueprint Medicines, an estimated $34M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, up from 48% a quarter earlier, followed by Technology and Financials.

Against the trend, Novo Holdings A/S opened a new position in BridgeBio Oncology worth $22.7M.

  • Novo Holdings A/S's largest Q3 2025 buy was BridgeBio Oncology: 1,961,317 shares worth $22.7M.
  • Novo Holdings A/S added most to Enliven Therapeutics in Q3 2025, an estimated $6.89M increase.
  • Novo Holdings A/S's biggest Q3 2025 reduction was Insmed, cutting an estimated $58.8M.
  • Novo Holdings A/S fully exited Blueprint Medicines in Q3 2025, selling an estimated $34M.
  • Novo Holdings A/S's ten largest holdings make up 73% of its $1.55B portfolio in Q3 2025.
  • Novo Holdings A/S opened 1 new position and closed 3 in Q3 2025.
  • Novo Holdings A/S's portfolio value rose 9.5% quarter-over-quarter to $1.55B.

Based on Novo Holdings A/S's 13F filing for Q3 2025, filed 14 Nov 2025.